Fluorescence in situ hybridization, when applied to chronic lymphocytic leukemia, is a laboratory technique used to detect specific DNA sequences within cells. This method employs fluorescent probes that bind to regions of chromosomes, highlighting genetic abnormalities associated with the disease. For example, it can identify deletions or translocations in chromosomes known to be linked to CLL prognosis and progression.
This diagnostic assay plays a crucial role in risk stratification and treatment planning for individuals diagnosed with CLL. The information gained from this analysis helps clinicians understand the genetic makeup of the leukemia cells, which can inform decisions about whether to initiate treatment, select specific therapies, and predict the likely course of the disease. Its application has advanced significantly since its introduction, evolving alongside advancements in genetic understanding and technology.